Loss of Taste: Drugs That Cause or Treat It

How Taste Perception Works at the Molecular Level

Taste buds contain 50 to 100 receptor cells that regenerate every 10 to 14 days from basal progenitor cells in the lingual epithelium. This rapid turnover makes them vulnerable to any drug that interferes with cell proliferation or zinc-dependent metalloenzymes. Gustatory signals travel via cranial nerves VII (chorda tympani), IX (glossopharyngeal), and X (vagus) to the nucleus tractus solitarius in the brainstem before reaching the insular cortex for conscious perception [1].

Saliva serves as the solvent medium that delivers tastant molecules to receptor proteins. Drugs that reduce salivary flow (anticholinergics, antidepressants, antihistamines) or alter salivary composition (by chelating zinc or changing pH) can blunt taste sensation without directly damaging taste buds. A 2019 review in the British Dental Journal identified over 300 medications with taste-altering properties, affecting an estimated 5 to 10% of the general population on chronic polypharmacy [2].

Zinc plays a central role in gustin (carbonic anhydrase VI), a salivary protein required for taste bud maturation. Drugs that chelate zinc or deplete it systemically can cause hypogeusia within weeks. This explains why zinc supplementation remains the most studied intervention for drug-induced and idiopathic taste disorders.

Drugs Most Commonly Causing Taste Disturbance

ACE inhibitors top the list. Captopril contains a sulfhydryl group that chelates zinc directly, producing a metallic or bitter taste in 2 to 7% of users [3]. Enalapril and lisinopril carry lower but measurable risk (0.5 to 1.5%). The effect is dose-dependent and typically reversible within 8 to 12 weeks of switching to an ARB.

Metronidazole produces a characteristic metallic taste in up to 12% of patients. The mechanism involves secretion of the drug itself into saliva at concentrations sufficient to activate bitter taste receptors [4]. Clarithromycin causes similar complaints in 3 to 19% of patients through 14-hydroxyclarithromycin accumulation in oral tissues.

Lithium alters sodium channel function on taste receptor cells, producing a persistent salty or metallic perception. A study published in the Journal of Clinical Psychopharmacology found dysgeusia in 8 to 35% of lithium-treated patients depending on serum levels [5].

Chemotherapy agents, particularly cisplatin, carboplatin, and 5-fluorouracil, damage taste progenitor cells directly. The MASCC/ISOO systematic review reported taste changes in 56 to 76% of patients receiving platinum-based regimens, with partial recovery beginning 3 to 6 months after the final cycle [6].

Other notable offenders include:

• Metformin (metallic taste in 3 to 5% of users, related to salivary secretion of the drug)
• Carbimazole and methimazole (ageusia reported as a rare but recognized adverse effect)
• Terbinafine (taste loss lasting up to 6 months post-discontinuation in rare cases)
• Topiramate (carbonated beverage dysgeusia due to carbonic anhydrase inhibition)
• Protease inhibitors (ritonavir causes bitter taste in up to 20% of HIV patients)

The Zinc Connection

Zinc deficiency, whether dietary or drug-induced, is the best-characterized reversible cause of hypogeusia. Robert Henkin's landmark work at the NIH Taste and Smell Clinic established that serum zinc levels below 70 mcg/dL correlate with measurable gustatory threshold elevation [7]. His protocol used zinc gluconate 140 mg daily (providing 20 mg elemental zinc) for 3 to 6 months.

A 2014 Cochrane review found limited but suggestive evidence supporting zinc supplementation for idiopathic taste disorders, noting heterogeneity in trial designs [8]. The strongest signal comes from patients with documented low zinc status or those taking zinc-chelating medications.

Drugs known to deplete zinc include loop diuretics (furosemide increases urinary zinc excretion by 50 to 100%), ACE inhibitors, penicillamine, and certain proton pump inhibitors. For patients on these medications who develop taste complaints, checking a serum zinc level is a reasonable first step before empiric supplementation.

The Endocrine Society has not issued formal guidelines on zinc for taste disorders, but clinical practice at specialized taste clinics typically involves a 4 to 6 week trial of zinc picolinate or gluconate 30 to 50 mg elemental zinc daily, with reassessment using taste strips or whole-mouth testing.

Diagnosis: When Loss of Taste Requires Workup

Primary care evaluation begins with distinguishing true taste loss from olfactory dysfunction. Patients frequently conflate the two. Pinching the nose while tasting solutions of sucrose, citric acid, sodium chloride, and quinine can isolate gustatory from retronasal olfactory pathways [9].

Validated tools include the Taste Strips test (measuring detection and identification thresholds for sweet, sour, salty, and bitter across anterior and posterior tongue regions) and electrogustometry, which applies electrical current to specific tongue areas to map cranial nerve function.

"Most patients who report taste loss actually have smell loss," noted Dr. Steven Bhatt in the American Academy of Otolaryngology clinical practice update (2020). "True isolated ageusia is rare and should prompt consideration of cranial nerve pathology, zinc deficiency, or medication effects."

Lab evaluation for persistent dysgeusia typically includes: complete blood count, serum zinc, vitamin B12, folate, fasting glucose (diabetes-related neuropathy), and thyroid function. MRI of the brain with attention to the skull base is warranted if cranial nerve dysfunction is suspected clinically.

Drug-induced dysgeusia is a diagnosis of exclusion confirmed by temporal correlation (onset within 2 to 12 weeks of starting the drug) and resolution after discontinuation. A structured medication review using resources like the WHO adverse drug reaction database (VigiBase) can identify less-recognized culprits.

Treatments That May Restore Taste Function

Drug withdrawal remains the most effective intervention when a medication is identified as the cause. The British Medical Journal Best Practice guidelines recommend a structured trial of discontinuation or substitution where clinically safe, with taste reassessment at 4 and 12 weeks [10].

For patients who cannot discontinue the offending agent, several adjunctive approaches have evidence:

Zinc supplementation (zinc gluconate 140 mg or zinc picolinate 30 mg elemental daily) for 3 to 6 months. Response rates vary from 25 to 50% in trials, with best results in patients with documented zinc deficiency [8].

Alpha-lipoic acid (600 mg daily) showed benefit in a randomized controlled trial of 44 patients with burning mouth syndrome and associated dysgeusia, published in the Journal of Oral Pathology and Medicine. Mean taste scores improved by 27% versus 5% in the placebo group over 2 months [11].

Saliva substitutes and sialogogues (pilocarpine 5 mg three times daily) address xerostomia-driven hypogeusia. Patients on anticholinergic medications who develop taste changes often benefit from increasing hydration and using sugar-free gum to stimulate residual salivary flow.

Taste training (exposure to concentrated solutions of basic tastants twice daily for 12 weeks) has shown preliminary benefit in post-viral ageusia, analogous to olfactory training protocols. A 2022 pilot study in Chemical Senses reported improved suprathreshold intensity ratings in 60% of participants [12].

For chemotherapy-induced dysgeusia, the MASCC/ISOO guidelines note that no single intervention has strong evidence, but recommend zinc supplementation during treatment and avoidance of metal utensils. Cooking with strong flavors (citrus, herbs, marinades) and serving food at room temperature may reduce metallic perception.

Post-COVID Taste Loss: A Special Case

SARS-CoV-2 damages sustentacular cells in the olfactory epithelium and may directly infect taste receptor cells via ACE2 receptors. A meta-analysis of 29 studies (N=14,595) published in The Lancet found that 38% of COVID-19 patients reported taste dysfunction, with median recovery at 21 days [13].

Persistent taste loss beyond 6 months occurs in 5 to 10% of infected individuals. These patients overlap substantially with long COVID phenotypes and may benefit from combined olfactory and gustatory training protocols.

"Patients with post-COVID taste loss lasting beyond 3 months should undergo formal gustatory testing to distinguish true ageusia from predominantly olfactory dysfunction," recommended the American Academy of Otolaryngology-Head and Neck Surgery in their 2021 position statement [14].

No pharmacologic intervention has strong evidence for post-COVID taste recovery specifically, though case series have reported benefit from intranasal corticosteroids (for accompanying olfactory loss), omega-3 fatty acids, and structured taste training.

When to Refer to a Specialist

Primary care management is appropriate for straightforward drug-induced cases with clear temporal correlation. Referral to otolaryngology or a dedicated taste and smell clinic is indicated when:

• Symptoms persist beyond 3 months after drug withdrawal
• No causative medication is identified
• Unilateral taste loss suggests cranial nerve pathology
• Associated symptoms (facial numbness, dysphagia) suggest brainstem or skull base disease
• The patient has received head and neck radiation (radiation-induced taste loss affects 70 to 90% of patients and may be permanent)

Specialized centers can perform regional gustatory mapping, which localizes dysfunction to specific cranial nerve territories and guides further imaging or nerve testing. The NIH Taste and Smell Clinic, though no longer active in its original form, established protocols now used at academic centers including the University of Pennsylvania Smell and Taste Center and the University of Dresden [15].

Practical Steps for Patients on Taste-Altering Medications

Patients who develop dysgeusia on a necessary medication should first confirm the association by reviewing timing. If the drug cannot be stopped, practical strategies include:

1. Request a serum zinc level and supplement if below 80 mcg/dL
2. Switch to plastic utensils if experiencing metallic taste
3. Rinse with sodium bicarbonate solution before meals (neutralizes bitter metallic compounds in saliva)
4. Add umami-rich foods (mushrooms, aged cheeses, soy) which stimulate separate glutamate receptors less affected by most drug classes
5. Discuss drug substitution with the prescriber (e.g., ARB for ACE inhibitor, azithromycin for clarithromycin)

For ACE inhibitor-related taste changes specifically, switching to an ARB eliminates the sulfhydryl-mediated zinc chelation mechanism while maintaining equivalent blood pressure control. A crossover study in Hypertension confirmed resolution of dysgeusia within 4 weeks of switching from captopril to losartan in 89% of affected patients [16].

Patients on long-term lithium should have zinc levels monitored annually and maintain awareness that taste changes may indicate rising serum lithium levels before other toxicity signs appear.